Tirzepatide was also tested in the SURPASS‐CVOT trial on patients with T2DM and atherosclerotic cardiovascular disease, where it was expected to give clear evidence of cardiovascular safety and superiority over dulaglutide, a GLP‐1 receptor agonist, in terms of lowering significant adverse cardiovascular events [9]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.